Comparative safety analysis of anti-interleukin-4/interleukin-13 inhibitors and Janus Kinase inhibitors in atopic dermatitis

J Am Acad Dermatol. 2024 Oct;91(4):768-771. doi: 10.1016/j.jaad.2024.06.064. Epub 2024 Jul 5.
No abstract available

Keywords: atopic dermatitis; atopic eczema; epidemiology; immunobiologics; immunomodulators; inflammation/inflammatory; outcomes (see also health services research).

Publication types

  • Letter
  • Comparative Study

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Dermatitis, Atopic* / drug therapy
  • Female
  • Humans
  • Interleukin-13* / antagonists & inhibitors
  • Interleukin-4* / antagonists & inhibitors
  • Janus Kinase Inhibitors* / adverse effects
  • Janus Kinase Inhibitors* / therapeutic use
  • Male

Substances

  • Janus Kinase Inhibitors
  • Interleukin-13
  • Interleukin-4
  • Antibodies, Monoclonal, Humanized